Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients

Annals of Oncology

Volumn 28, Issue 6, 2017, Pages 1325-1332

  Vidal, J ^a   Muinelo, L ^b   Dalmases, A ^a   Jones, F ^c   Edelstein, D ^c   Iglesias, M ^a   Orrillo, M ^a   Abalo, A ^b   Rodriguez C ^b   Brozos, E ^b   Vidal, Y ^b   Candamio, S ^b   Vazquez F ^b   Ruiz, J ^b   Guix, M ^a   Visa, L ^a   Sikri, V ^c   Albanell, J ^a,d   Bellosillo, B ^a,b   Lopez R ^b   Montagut, C ^a   more..

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c SYSMEX CORPORATION   (Japan)

^d UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Colorectal cancer; CtDNA; Heterogeneity; Liquid biopsy; RAS mutations; Tumor dynamics

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CHLOROPLAST DNA; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CODON; CONTROLLED STUDY; DRUG RESPONSE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYZER; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LONGITUDINAL STUDY; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; MUTANT; MUTATIONAL ANALYSIS; ONCOGENE RAS; PERITONEUM METASTASIS; PLASMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TUMOR LOCALIZATION; TUMOR VOLUME; WILD TYPE; ANTAGONISTS AND INHIBITORS; BLOOD; COLORECTAL TUMOR; DNA MUTATIONAL ANALYSIS; METASTASIS; PATHOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENES, RAS; HUMANS; MONITORING, PHYSIOLOGIC; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 85021160354     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx125     Document Type: Article

References (15)

1. Van Cutsem E, Cervantes A, Adam R. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27(8): 1386-1422.
2. MisaleYaeger SR, Hobor S. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486(7404): 532-536.
3. Diaz LA Jr, Williams RT, Wu J. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486(7404): 4-7.
4. Van Emburgh BO, Arena S, Siravegna G. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun 2016; 7: 13665.
5. Montagut C, Dalmases A, Bellosillo B. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 18(2): 221-223.
6. Bettegowda C, Sausen M, Leary RJ. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6(224): 224ra24.
7. Diehl F, Schmidt K, Choti MA. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14(9): 985-990.
8. Morelli MP, Overman MJ, Dasari A. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol OffJ Eur Soc Med Oncol/ESMO 2015; 26(4): 731-736.
9. Arena S, Bellosillo B, Siravegna G. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin Cancer Res 2015; 21(9): 2157-2166.
10. Tie J, Kinde I, Wang Y. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 2015; 26(8): 1715-1722.
11. Siravegna G, Mussolin B, Buscarino M. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015; 21(7): 795-801.
12. Toledo R, Cubillo AA, Vega E. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget 2016 [epub ahead of print].
13. Tabernero J, Lenz H-J, Siena S. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015; 16(8):937-948.
14. Azuara D, Santos C, Lopez-Doriga A. Nanofluidic digital PCR and extended genotyping of RAS and BRAF for improved selection of metastatic colorectal cancer patients to anti-EGFR therapies. Mol Cancer Ther 2016; 15: 14-21.
15. Gonzalez de Castro D, Angulo B, Gomez B. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br J Cancer 2012; 107(2): 345-351.